SEER trades 145.4% below Wall Street's consensus target of $4.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes SEER achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Seer, Inc. (SEER) has a Wall Street consensus price target of $4.00, based on estimates from 4 covering analysts. With the stock currently trading at $1.63, this represents a potential upside of +145.4%. The company has a market capitalization of $90M.
Analyst price targets range from a low of $4.00 to a high of $4.00, representing a 0% spread in expectations. The median target of $4.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 1 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 1 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, SEER trades at a trailing P/E of -1.3x. Analysts expect EPS to grow +10.7% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 QTRXQuanterix Corporation | $137M | $2.90 | $3.00 | +3.6% | Buy | — | 10 |
 CDNACareDx, Inc | $4.1B | $78.56 | $75.25 | -4.2% | Buy | 44.1x | 14 |
 NAUTNautilus Biotechnolgy, Inc. | $284M | $2.23 | $3.50 | +57.0% | Buy | — | 5 |
 ILMNIllumina, Inc. | $32.2B | $213.13 | $252.73 | +18.6% | Buy | 39.4x | 50 |
 PACBPacific Biosciences of California, Inc. | $702M | $2.26 | $1.93 | -14.4% | Buy | — | 18 |
 BRKRBruker Corporation | $9.3B | $61.31 | $67.00 | +9.3% | Buy | 28.9x | 33 |
 TWSTTwist Bioscience Corporation | $7.5B | $120.79 | $153.70 | +27.2% | Buy | — | 15 |
 BEAMBeam Therapeutics Inc. | $2.7B | $26.41 | $66.00 | +149.9% | Buy | — | 28 |
 RXRXRecursion Pharmaceuticals, Inc. | $1.8B | $3.52 | $5.90 | +67.6% | Hold | — | 10 |
 TMOThermo Fisher Scientific Inc. | $258.2B | $694.76 | $694.27 | -0.1% | Buy | 27.5x | 43 |
Quick answers to the most common questions about buying SEER stock.
The consensus Wall Street price target for SEER is $4, representing 145.4% upside from the current price of $1.63. With 4 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
SEER has a consensus rating of "Hold" based on 4 Wall Street analysts. The rating breakdown is mixed, with 2 Hold ratings making up the largest segment. The consensus 12-month price target of $4 implies 145.4% upside from current levels.
SEER's current price is $1.63 with a consensus target of $4 (145.4% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $4 for SEER, while the most conservative target is $4. The consensus of $4 represents the median expectation. These targets typically reflect 12-month expectations.
SEER is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 2 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SEER stock forecast based on 4 Wall Street analysts shows a consensus price target of $4, with estimates ranging from $4 (bear case) to $4 (bull case). The median consensus rating is "Hold".
Wall Street analysts are very optimistic on SEER, with a "Hold" consensus rating and $4 price target (145.4% upside). 1 of 4 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SEER analyst price targets range from $4 to $4, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $4 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.